Advaxis receives notice of allowance from USPTO for three patent applications Advaxis announced that the USPTO has issued a notice of allowance for three U.S. patent applications with claims of each application related to the company's proprietary cancer immunotherapy platform technology. The patent with the latest date of expiry is 2030, without taking into account patent term extension. The three patent applications allowed by the USPTO cover composition of matter and methods of use for combining the Advaxis proprietary immunogenic but non-toxic recombinant tLLO fused to full and partial antigens of particular interest in the treatment of multiple cancers, including B-cell lymphoma in both humans and animals. Additional patent applications also allowed by the USPTO encompass a method of use targeting multiple critical structural and identifying elements associated with B-cells and B-cell lymphomas and allow targeting of multiple structural peptides at the same time. Also allowed separately are composition of matter and methods of use to accommodate the targeting of Advaxis treatments toward factors that are essential for tumors or metastases to form new blood vessels or that are expressed by tumor blood vessels. A method of use is allowed where multiple targets associated with angiogenesis can be targeted at the same time in animals as well as humans. These include, but are not limited to, HER2 and VEGFr2.